The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Generic Drug Application User Fees Will Be Lower in FY 2015; PDUFA Fees Will Increase By Roughly the Same Amount Jul. 31, 2014
- LDT Oversight A Victory For Drug Developers But FDA Will Take Time To Take Unapproved Tests Off The Market Jul. 31, 2014
- Baxter/Halozyme HyQvia Gains Strong Panel Support, Despite Skeptical Review; Eprex Immunogenicity Scare Lingers At FDA Jul. 31, 2014
See More Research Notes